Related Experiment Videos
New medicinal treatment for severe gingivostomatitis
S Katayama1, J Ohshita, K Sugaya
1Department of Pharmacy, Japan Medical Hospital, Tokyo, Japan.
International Journal of Molecular Medicine
|December 16, 1998
Summary
A new poraprezinc-sodium alginate suspension (P-AG) effectively treated severe gingivostomatitis in chemotherapy patients. All 15 patients showed excellent or good responses, highlighting P-AG
Area of Science:
- Oncology
- Pharmacology
- Biomaterials
Background:
- Severe gingivostomatitis is a debilitating side effect of chemotherapy.
- Current treatments offer limited efficacy for severe cases with hemorrhagic erosion and ulcers.
Observation:
- A novel poraprezinc-sodium alginate suspension (P-AG) was developed for severe gingivostomatitis.
- The suspension was administered to 15 patients undergoing chemotherapy.
Findings:
- P-AG demonstrated high utility, with 10 patients achieving an excellent response and 5 a good response.
- The treatment was effective in managing severe gingivostomatitis, including hemorrhagic erosion and ulcers.
Implications:
- P-AG shows significant therapeutic potential for chemotherapy-induced gingivostomatitis.
- The formulation's mechanism involves mucosal protection, free radical scavenging, tissue repair, and hemostasis.
- This offers a promising new treatment option for improving patient quality of life during cancer therapy.